Abstracts tagged "Disease Activity"

Abstract Number: 1103 • ACR Convergence 2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Kayla Chubbs¹, Carrie Ye², Shahin Jamal³, Marie Hudson⁴, Janet Pope⁵, Tom Appleton⁶, Sabrina Hoa⁷, Alexandra Saltman⁸, Megan Himmel⁸, Nancy Maltez⁹, Faiza Khokhar¹⁰, Alexandra Ladouceur¹¹, Ines Colmegna¹², May Choi¹³, Manar Elsayed² and Janet Roberts¹, ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ¹⁰Hamilton Ontario, Hamilton, ON, Canada, ¹¹University of Montreal, Montreal, QC, Canada, ¹²The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹³University of Calgary, Calgary, AB, Canada
Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
Abstract Number: 0803 • ACR Convergence 2025
Improved Efficacy and Safety Outcomes in Patients with SLE Treated with Belimumab (BEL) Versus Immunosuppressants (IS), in Addition to Antimalarials (AM) and Glucocorticoids (GC): A Post Hoc Summary of Five Phase 3 Trials
Mariele Gatto¹, Karen H. Costenbader², Andreas Schwarting³, Julia Harris⁴, Ciara O'Shea⁵, Roger A. Levy⁶ and Andrea Doria⁷, ¹Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Turin, Italy, ²Harvard Medical School and Brigham and Women's Hospital, Boston, MA, ³Johannes Gutenberg University Mainz, University Medical Centre, Mainz, Germany, ⁴GSK, Biostatistics, London, United Kingdom, ⁵Global Medical Affairs, GSK, Dublin, Ireland, ⁶GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, ⁷University of Padova, Padova, Italy
Background/Purpose: Chronic GC and IS use increases damage accrual and mortality. The 2023 EULAR SLE recommendations support initiation of biologics such as BEL, a human…
Abstract Number: 0448 • ACR Convergence 2025
Implementing Artificial Intelligence to Identify Rheumatoid Arthritis Flares Using Electronic Medical Records Processed with Privacy-Preserving Large Language Models: A Pilot Study
Ioannis Koulas¹, Nikolaos Tsaftaridis², Marios Gkionis³, Giancarlo Paternoster⁴, Sunit Jariwala⁵ and Konstantinos Loupasakis⁶, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²The Feinstein Institutes for Medical Research, Manhasset, ³NTNU, Department of Engineering Cybernetics, Trondheim, Norway, ⁴Albert Einstein College of Medicine, Bronx, NY, ⁵Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, ⁶Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Although Large Language Models (LLMs) have been successfully used in the analysis of data from Electronic Health Records (EHRs), their implementation in the field…
Abstract Number: 1450 • ACR Convergence 2025
The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
Patrick-Pascal Strunz¹, Tobias Heusinger², Maxime Le Maire², Anna Fleischer³, Karsten Sebastian Luetkens⁴, Patricia Possler², Michael Gernert¹, Hannah Labinsky⁵, Robert Leppich⁶, Astrid Schmieder⁷, Ludwig Hammel⁸, Billy Sperlich⁹, Matthias Fröhlich¹ and Marc Schmalzing¹⁰, ¹University Hospital of Wuerzburg, Department of Medicine II, Rheumatology/ Immunology, Wuerzburg, Germany, ²University of Wuerzburg, Wuerzburg, Germany, ³University Hospital of Wuerzburg, Department of Medicine II, Psychosomatics, Wuerzburg, Germany, ⁴University Hospital of Wuerzburg, Institute of Diagnostic and Interventional Radiology, Wuerzburg, Germany, ⁵University Hospital of Wuerzburg, Würzburg, Germany, ⁶University Hospital of Wuerzburg, Chair of Software Engineering (Informatik II), Department of Computer Science, Wuerzburg, Germany, ⁷University Hospital Würzburg, Department of Dermatology, Venereology, and Allergology, Wuerzburg, Germany, ⁸Deutsche Vereinigung Morbus Bechterew e. V., Schweinfurt, Germany, ⁹Integrative and Experimental Exercise Science and Training, Institute for Sports Science, Wuerzburg, Germany, ¹⁰Department of Medicine II, Rheumatology/ Immunology,University Hospital of Wuerzburg, Wuerzburg, Bayern, Germany
Background/Purpose: Axia is a novel digital therapeutic (DTx) specifically designed for patients with axial spondyloarthritis (axSpA), in compliance with the European Medical Device Regulation (MDR).…
Abstract Number: 2616 • ACR Convergence 2025
Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis
Ryan Clark¹, Sally Almahdawi¹, Carolina Alvarez², Rumey Ishizawar³ and Thuyvan Phan⁴, ¹UNC Eshelman School of Pharmacy, Chapel Hill, NC, ²University of North Carolina at Chapel Hill, Miami, FL, ³UNC Division of Rheumatology, Allergy and Immunology and TARC, Chapel Hill, NC, ⁴UNC Health, Chapel Hill, NC
Background/Purpose: The University of North Carolina (UNC) Hospitals Rheumatology Clinic is utilizing the Clinical Disease Activity Index (CDAI) in patients with rheumatoid arthritis (RA) per…
Abstract Number: 2308 • ACR Convergence 2025
Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
AUGUSTA ORTOLAN¹, Désirée Van Der Heijde², Laure Gossec³ and Sofia Ramiro⁴, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Health-related quality of life (HRQoL) is an overarching outcome in axial spondyloarthritis (axSpA), and is considered influenced by disease activity and physical function. However,…
Abstract Number: 2062 • ACR Convergence 2025
Immune Cell Signatures Associated with Disease Activity in Dermatomyositis Across Autoantibody Subtypes
Jeffrey Sagun¹, Melissa Leeolou¹, Nicholas Geraci², Andrew Bender³, Fatima Strand², David Fiorentino¹ and Kavita Sarin¹, ¹Department of Dermatology, Stanford University Medical Center, Stanford, CA, ²EMD Serono, Billerica, MA, ³AbbVie, Worcester, MA
Background/Purpose: Dermatomyositis (DM) is a heterogeneous multisystem autoimmune disease characterized by inflammation of the skin, muscle, and lung. Identifying the immune cells that drive disease…
Abstract Number: 1503 • ACR Convergence 2025
Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Ranjan Gupta, Nilanchali Singh, Nisha Jawaliya, Rudra Prosad Goswami, Soniya Dhiman and Parul baisoya, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Systemic Lupus Erythematosus (SLE) disease activity can affect the normal functioning of the patients. This functioning in various domains can be assessed using quality…
Abstract Number: 1357 • ACR Convergence 2025
Measuring Rheumatoid Arthritis Outcomes Using Machine Learning Imputed Disease Activity Scores
Jue Hou¹, Feiqing Huang², Gregory McDermott³, Jun Wen⁴, Mary Jeffway³, Ying Qi⁵, Yunqing Han³, Tianrun Cai⁶, Florence Bourgeois⁴, Katherine Liao⁷ and Tianxi Cai², ¹University of Minnesota, Minneapolis, MN, ²Harvard T.H. Chan School of Public Health, Boston, ³Brigham and Women's Hospital, Boston, ⁴Harvard Medical School, Boston, ⁵Brigham and Women’s Hospital, Boston, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: Validated rheumatoid arthritis (RA) disease activity measures such as the Disease Activity Score-28 (DAS28) are used in clinical trials but not universally recorded in…
Abstract Number: 1081 • ACR Convergence 2025
Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
Ramsha Riaz¹, Lifang Zhang², Andrea Berger², Hema Srinivasan², Lisa Schroeder³ and Jonida Cote⁴, ¹Geisinger Medical Center, Danville, PA, ²Geisinger Health System, Danville, PA, ³Geisinger, Danville, PA, ⁴Geisinger Health System, Wilkes-Barre, PA
Background/Purpose: Recognizing health care disparities in Rheumatoid Arthritis is crucial to improving outcomes. This study analyzes factors contributing to RA care inequities.Methods: We examined RA…
Abstract Number: 0791 • ACR Convergence 2025
Disagreements in Disease Activity Measures in an Evaluation of SLE Outcome Measures in Telemedicine
Leila Khalili¹, Cynthia Aranow², Mimi Kim³, Diane Kamen⁴, Cristina Arriens⁵, Alberto Nordmann-Gomes⁶, Maya Souvignier⁶, Wei Tang⁷, Stephen Suh⁸, Maria Dall'Era⁹, Meghan mackay¹⁰ and Anca Askanase¹, ¹Columbia University Medical Center, New York, NY, ²Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Medical University of South Carolina, Johns Island, SC, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Columbia University Irving Medical Center, New York, NY, ⁷Westchester Medical Center, Valhalla, NY, ⁸Columbia University Irving Medical Center, New York City, NY, ⁹Division of Rheumatology, University of California, San Francisco, CA, ¹⁰Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We previously described the top-line results of our study and the high correlations between virtual SLE disease activity measures (DAM) and those obtained during…
Abstract Number: 0444 • ACR Convergence 2025
Low Disease Activity: Good Enough?
Emily Thoman¹, Sebastiano Porcu¹ and Martin Bergman², ¹Lankenau Medical Center, Wynnewood, PA, ²Drexel University College of Medicine, Philadelphia
Background/Purpose: Treat-to-target is the guiding principle and therapeutic strategy for rheumatoid arthritis (RA) treatment. Escalation of treatment is based on the regular assessment of disease…
Abstract Number: 0236 • ACR Convergence 2025
Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease
Laura Bucci¹, Sebastian Böltz¹, Melanie Hagen¹, Danae-Mona Nöthling¹, Tobias Rothe², Carlo Tur¹, Andreas Wirsching¹, Janina Auth³, jochen wacker¹, Markus Eckstein⁴, Stefano Alivernini⁵, Aline Bozec¹, Christina Bergmann¹, Maria Antonietta D'Agostino⁶, Maria Gabriella Raimondo¹, Georg Schett⁷ and Ricardo Grieshaber-Bouyer⁸, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁵Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁶Division of Rheumatology and Clinical Immunology - Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸University Hospital Erlangen, Erlangen, Germany
Background/Purpose: T cell engagers (TCEs) are a promising therapeutic strategy to treat autoimmune diseases (AID). However, long-term data remain limited.Methods: Patients with treatment-refractory AID were…
Abstract Number: 2600 • ACR Convergence 2025
Deconstructing Lupus Nephritis Kidney Tissue at Single-Cell Resolution
Nicholas Sugiarto¹, Michelle Curtis², Siddarth Gurajala², Thomas Eisenhaure³, Qian Xiao⁴, Joseph Mears⁵, Arnon Arazi⁶, Paul Hoover⁷, Celine Berthier⁸, Saori Sakaue⁹, Andrea Fava¹⁰, David Hildeman¹¹, E. Steve Woodle¹², Brad Rovin¹³, Jennifer Barnas¹⁴, Maria Dall'Era¹⁵, Chaim Putterman¹⁶, Diane Kamen¹⁷, Maureen McMahon¹⁸, Jennifer Grossman¹⁹, Kenneth Kalunian²⁰, Jeffrey Hodgin²¹, Fernanda Payan Schober²², Mariko Ishimori²³, Michael Weisman²³, William Apruzzese²⁴, Joel Guthridge²⁵, Michael Brenner²⁶, Jennifer Anolik²⁷, David Wofsy²⁸, Judith James²⁵, Deepak Rao⁷, Anne Davidson²⁹, Michelle Petri³⁰, Jill Buyon³¹, Nir Hacohen³², Betty Diamond³³ and Soumya Raychaudhuri⁷, ¹Harvard Medical School, Brookline, MA, ²Harvard Medical School, Boston, ³Broad Institute, Cambridge, MA, ⁴Harvard Medical School, Boston, MA, ⁵Michigan University, Ann Arbor, MI, ⁶Feinstein Institutes for Medical Research, Acton, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Washington, Yokohama, Japan, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Cincinnati Children's Hospital, Cincinnati, OH, ¹²UC Health, Cincinnati, ¹³The Ohio State University, Columbus, OH, ¹⁴University of Rochester, Rochester, NY, ¹⁵Division of Rheumatology, University of California, San Francisco, CA, ¹⁶Albert Einstein College of Medicine, Safed, Israel, ¹⁷Medical University of South Carolina, Johns Island, SC, ¹⁸UCLA David Geffen School of Medicine, Los Angeles, CA, ¹⁹UCLA, Sherman Oaks, CA, ²⁰UC San Diego, La Jolla, CA, ²¹University of Michigan, Ann Arbor, ²²TTUHSC, El Paso, TX, ²³Cedars-Sinai Medical Center, Los Angeles, CA, ²⁴Pfizer, Boston, ²⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁶Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁷University of Rochester Medical Center, Rochester, NY, ²⁸University of California San Francisco, SF, CA, ²⁹Feinstein Institutes for Medical Research, Manhasset, NY, ³⁰Johns Hopkins University School of Medicine, Timonium, MD, ³¹NYU Grossman School of Medicine, New York, NY, ³²Broad Institute of MIT Harvard, Cambridge, MA, ³³The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) is a heterogeneous disease driven by diverse immune and tissue cell types. We defined the cell states in the tissue and…
Abstract Number: 2295 • ACR Convergence 2025
Autoantibody Profiles and Their Association with Organ Involvement in Primary Sjögren’s Syndrome: Insights from ESSDAI
Deepak Rath¹, Sholen Acharya² and Dr Alakendu Ghosh³, ¹John H Stroger Hospital Jr of Cook County, Chicago, Illinois, USA, ⁶⁰⁶¹², Chicago, IL, ²Department of Reproductive Medicine and Surgery, Government Medical College Thiruvananthapuram, Kerala, India, ⁶⁹⁵⁰⁰⁴, Chicago, IL, ³Self employed, Kolkata, West Bengal, India
Background/Purpose: To evaluate the clinical manifestations, systemic disease activity, and serological profile of patients of Primary Sjögren’s syndrome, and to assess associations between specific autoantibodies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].